FutureChem Signs Technology Licensing Agreement for Prostate Cancer Diagnostic Drug in China
[Asia Economy Reporter Geum Boryeong] FutureChem announced on the 1st that it has signed a technology transfer agreement for the prostate cancer diagnostic radiopharmaceutical FC303 in China with HTA CO., LTD.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- JD Vance: "Iran Must Agree to Abandon Nuclear Weapons... Military Action Remains an Option"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The upfront payment and milestones amount to 2 million USD (approximately 2.37 billion KRW), which corresponds to 29% of last year's consolidated sales. The contract period is 20 years from the date of the agreement.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
